688163 Stock Overview
Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sale of antitoxin and antiserum products in China.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Shanghai Serum Bio-Technology Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥13.02 |
52 Week High | CN¥24.98 |
52 Week Low | CN¥10.98 |
Beta | 0.35 |
1 Month Change | -15.45% |
3 Month Change | -26.73% |
1 Year Change | -46.42% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -76.46% |
Recent News & Updates
Recent updates
Shareholder Returns
688163 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -9.1% | -5.9% | -4.9% |
1Y | -46.4% | -29.3% | -21.1% |
Return vs Industry: 688163 underperformed the CN Biotechs industry which returned -29.3% over the past year.
Return vs Market: 688163 underperformed the CN Market which returned -21.1% over the past year.
Price Volatility
688163 volatility | |
---|---|
688163 Average Weekly Movement | 9.4% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 8.7% |
10% most volatile stocks in CN Market | 12.4% |
10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 688163's share price has been volatile over the past 3 months.
Volatility Over Time: 688163's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 329 | n/a | www.serum-china.com.cn |
Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sale of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shanghai, China.
Shanghai Serum Bio-Technology Co., Ltd. Fundamentals Summary
688163 fundamental statistics | |
---|---|
Market cap | CN¥1.32b |
Earnings (TTM) | CN¥40.67m |
Revenue (TTM) | CN¥190.20m |
34.6x
P/E Ratio7.4x
P/S RatioIs 688163 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688163 income statement (TTM) | |
---|---|
Revenue | CN¥190.20m |
Cost of Revenue | CN¥0 |
Gross Profit | CN¥190.20m |
Other Expenses | CN¥149.53m |
Earnings | CN¥40.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 27, 2024
Earnings per share (EPS) | 0.38 |
Gross Margin | 100.00% |
Net Profit Margin | 21.38% |
Debt/Equity Ratio | 1.3% |
How did 688163 perform over the long term?
See historical performance and comparison